MARC Record from Library of Congress

LEADER: 03368cam a22003377a 4500
001 2012943829
003 DLC
005 20150128080746.0
008 120709s2012 nyua b 001 0 eng d
010 $a 2012943829
016 7 $a016107612$2Uk
020 $a9781627030076 (alk. paper)
020 $a1627030077 (alk. paper)
035 $a(OCoLC)ocn788252989
040 $aBTCTA$beng$cBTCTA$dUKMGB$dRML$dYDXCP$dCOU$dEYM$dOCLCO$dNUI$dCOO$dDLC
042 $alccopycat
050 00 $aRS420$b.R365 2012
082 00 $a615.1/9$223
245 00 $aRational drug design :$bmethods and protocols /$cedited by Yi Zheng.
260 $aNew York :$bHumana Press ;$bSpringer,$cc2012.
300 $axi, 230 p. :$bill. (some col.)$c27 cm.
490 1 $aMethod in molecular biology,$x1064-3745 ;$v928
490 1 $aSpringer protocols
504 $aIncludes bibliographical references and index.
505 00 $tOn setting up and assessing docking simulations for virtual screening /$rJacek Biesiada, Aleksey Porollo, and Jaroslaw Meller --$tVirtual ligand screening combined with NMR to identify Dvl PDZ domain inhibitors targeting the Wnt signaling /$rJufang Shan and Jie J. Zheng --$tRational design of Rho GTPase-targeting inhibitors /$rXun Shang and Yi Zheng --$tRational design of peptide ligands against a glycolipid by NMR studies /$rWenyong Tong ... [et al.] --$tCombinatorial strategy for the acquisition of potent and specific protein tyrosine phosphatase inhibitors /$rSheng Zhang ... [et al.] --$tIdentification of allosteric inhibitors of p21-activated kinase /$rJulien Viaud and Jeffrey R. Peterson --$tUsing a modified yeast two-hybrid system to screen for chemical GEF inhibitors /$rAnne Blangy and Philippe Fort --$tRandom mutagenesis of peptide aptamers as an optimization strategy for inhibitor screening /$rNathalie Bouquier ... [et al.] --$tScreening strategy for trapping the inactive conformer of a dimeric enzyme with a small molecule inhibitor /$rCharles S. Craik and Tina Shahian --$tUse of a fluorescent ATP analog to probe the allosteric conformational change in the active site of the protein kinase PDK1 /$rValerie Hindie, Laura A. Lopez-Garcia, and Ricardo M. Biondi --$tAffinity purification of protein kinases that adopt a specific inactive conformation /$rPratistha Ranjitkar and Dustin J. Maly --$tDetermination of the kinetics and thermodynamics of ligand binding to a specific inactive conformation in protein kinases /$rSanjay B. Hari, Pratistha Ranjitkar, and Dustin J. Maly --$tPurification and specific assays for measuring APE-1 endonuclease activity /$rAdrian Esqueda ... [et al.] --$tIn vitro screening to identify drug-resistant mutations for target-directed chemotherapeutic agents /$rMohammad Azam --$tUtilizing antagomiR (antisense microRNA) to knock down microRNA in murine bone marrow cells /$rChinavenmeni S. Velu and H. Leighton Grimes --$tSynthesis, conjugation, and labeling of multifunctional pRNA nanoparticles for specific delivery of siRNA, drugs, and other therapeutics to target cells /$rPeixuan Guo ... [et al.] --$tMouse models for tumor metastasis /$rShengyu Yang, J. Jillian Zhang, and Xin-Yun Huang.
650 0 $aDrugs$xDesign.
650 12 $aDrug Design.
655 2 $aLaboratory Manuals.
700 1 $aZheng, Yi$4edt
830 0 $aMethods in molecular biology (Clifton, N.J.) ;$vv. 928.
830 0 $aSpringer protocols.